Genfit reports the entry into Phase I trials of GFT505, the company’s molecule for the simultaneous treatment of several risk factors of cardiometabolic disease.
According to a Genfit spokesperson, GFT505, a multimodal, pluripotent compound, acts on the molecular level by activating PPAR (peroxisome proliferator-activated receptors) nuclear receptors, which play a central role in the regulation of lipid metabolism and the control of glycemia.
“With a completely original profile—Pan-sPPARm, selective PPAR modulator, with a preferential action on the PPAR alpha family—and evaluated by Genfit’s proprietary SNuRM technology platform, GFT505 targets a wide range of indications: mixed dyslipidemia, type II diabetes, and atherosclerosis,” explains Dean Hum, vp and CSO.
